Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Inclusion Criteria:

* Not currently on drug therapy for type 2 diabetes
* Blood glucose criteria must be met
* Body mass index (BMI) in the range 22-45

Exclusion Criteria:

* History of type 1 diabetes
* Evidence of significant diabetic complications
* Serious cardiovascular events within the past 6 months
* Laboratory value abnormalities as defined by the protocol
* Other protocol-defined exclusion criteria may apply
B: Inclusion Criteria:

* Recently diagnosed type 2 diabetes
* No previous anti-diabetic medications

Exclusion Criteria:

* Heart failure
* Renal disease
* Liver disease
* Life-threatening diseases
C: Inclusion Criteria:

* Newly Diagnosed Type 2 Diabetes Mellitus patients not receiving any medication for diabetes
* HbA1c ranging from 7.0% to ≤ 8.5%
* Body Mass Index (BMI) ≥ 19.0 to ≤ 25.0 kg/m2
* Male and female subjects of age between 20 - 60 years shall be selected
* Adult subjects willing to give informed consent
* Subject must be available for and willing to attend all evaluation visits
* Willingness to follow the protocol requirements as evidenced by written informed consent
* Subject must have access to telephone for calling into the clinical center as part of test product compliance

Exclusion Criteria:

* Type 1 diabetes
* BMI ≤18.99 kg/m2 or\> 25 kg/m2
* Presence of severe vascular complications
* Indications for use of insulin
* Elevated serum levels of lipase and amylase (\>1.5 ULN)
* Gamma-glutamyltransferase \>2 times upper limit of normal (ULN) at Visit1, confirmed by repeated measure within 3 working days
* Urine albumin: creatinine ratio (UACR) \>1800 mg/g (\>203.4 mg/mmol)
* Subjects below the age of 20 years and above the age of 60 years
* History of any drug abuse in the past 12 months
* History of hypersensitivity to study drugs and related drugs or excipients in the formulation.
* History of allergy to vegetables and or food substances and or any other manifestations suggestive of hypersensitivity reactions
* Subject who is not willing to participate in the study
* Clinically significant abnormal laboratory results at screening.
* Subject is being treated for severe active infection of any type
* A female subject who is breast-feeding, pregnant, or intends to become pregnant during the study
* Subject with clinically relevant uncontrolled medical condition (e.g hematologic renal hepatic neurology cardiac or respiratory)
* Subject has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years
* Participating in a clinical research trial within 30 days prior to screening
* Donated blood 3 months prior to first study visit and during the study period
* Individuals who are cognitively impaired and or who are unable to give informed consent
* Known HIV or Hepatitis B or C positive
* Any other health or mental condition that in the Investigator's opinion may adversely affect the subjects ability to complete the study or its measures or that may pose significant risk to the subject
D: Inclusion Criteria:

* Type 2 diabetes
* Currently using insulin for at least 3 months with a conventional insulin regimen with or without oral medications
* Glycosylated hemoglobin (HbA1c) greater than or equal to 7% and less than or equal to 11%
* Willing to inject subcutaneous medication
* Willing to monitor blood glucose levels and adjust insulin dose
* Willing to maintain a study diary
* Body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m\^2)
* Stable weight for 3 months prior to screening
* Females of child bearing potential must test negative for pregnancy at screening and be willing to use a reliable method of birth control during the study and for 1 month following the last dose of study drug

Exclusion Criteria:

* Type 1 Diabetes
* Previous therapy with glucagon-like peptide 1 (GLP-1) agonists within 3 months prior to screening
* 1 or more episodes of ketoacidosis within 6 months prior to screening
* Have been treated with prescription or over the counter medication to promote weight loss within 3 months prior to screening
* Estimated glomerular filtration rate (eGFR) less than or equal to 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) at screening
* Taking steroids for greater than 14 days except for topical, eye, nasal, or inhaled
* History of heart failure, New York Heart Classification III or IV within 2 months prior to screening
* Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking medications that directly affect GI motility
* Acute or chronic hepatitis or pancreatitis
* Self or family history of 2A or type 2B multiple endocrine neoplasia or medullary C-Cell hyperplasia
* Serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/mL) at screening
* Organ transplant except cornea
* Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis
* History of or active malignancy except skin or in situ cervical or prostate cancer within the last 5 years
* Known drug or alcohol abuse
* Have enrolled in another clinical trial within the last 30 days
* Have previously signed an informed consent or participated in a LY2189265 study

Answer: A